[Experiences with the preventive use of aminophylline (Euphylline) in apnea and periodic respiration in infants].

Sleep apnea and periodic breathing in infants are the result of a mild hypoxia and they are the requirement for SIDS. As a results of the modern medicine each 4.-5.

[Apneas and periodic breathing in mature newborn infants].

50 healthy term newborn infants without a history of sudden infant death syndrome among their relationship were investigated between the second and fourth day of life using a modified test of Brady and McCann. In a thermoneutral environment pneumograms (respiration by thoracic impendance, heart rate, tcpO2) were obtained with an FiO2 of 21, 16, and 30% oxygen. In 12 of the 50 sleeping infants (24%) apnea periods or periodic breathing were observed with an FiO2 of 16%.

[Recurrent hemolytic-uremic syndrome with positive immunofluorescence].

The hemolytic uremic syndrome is a disease of infancy, its major clinical manifestations include reversible thrombocytopenia, hemolytic anemia, and renal failure. Although a great number of patients with HUS have been published, relapses as well as positive immunofluorescence studies are rare findings. In our patient the disease began at age of 7 years and recovered completely.

[Infantile transitory distal renal tubular acidosis with bicarbonate loss].

Apart from the classic distal renal tubular acidosis (RTA), the proximal RTA, and a few cases of distal RTA and renal bicarbonate wasting we know only 2 cases of infantile transient distal RTA with bicarbonate wasting. A 3 month-old male patient is admitted because of deficient suction, vomiting and dehydration. Despite a strong metabolic acidosis (pH 7,09, bicarbonate 8,6 mMol/l, chloride 110 meq/l) the urine is constantly alkaline; clinically the disease manifests itself in the form of an alkali-resistant RTA.

Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

Following implant of cotton thread-carrying 3-methyl-cholanthrene into the pancreas tissue of 90 C57BL/6 and 60 BALB/c mice, 13 developed ductal adenocarcinomas. Two of these tumors, both of C57BL/6 origin (Panc 02 and 03), were established in serial s.c.

Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect.

Herein we have considered the types of tumor stem cell heterogeneity that might account for (a) fluctuating degrees of response to chemotherapy in similarly treated individuals bearing a particular neoplasm, and (b) classifications of cancers by chemotherapeutic effect. Fluctuating ratios of T/R to T/O stem cells, as predicted by the mutation theory, will account for (a). In different circumstances at least three phenomena might account for (b): growth fraction differences, differences in T/R to T/O stem cell ratios, or differences with respect to pharmacologic sanctuaries.

Establishment of cross-resistance profiles for new agents.

Sublines of murine leukemias (L1210 and P388) and solid tumors selected for resistance to representatives of all of the chemical and functional classes of clinically useful anticancer drugs have been isolated and established in serial in vivo passage and, in some cases, in vitro culture. Extensive resistance, cross-resistance, and collateral-sensitivity patterns have been established with most of the sublines of the drug-resistant murine leukemias under treatment with greater than 100 different established and clinically useful anticancer drugs or new candidate anticancer drugs currently under study. Patients selected for inclusion in phase I-II trials usually have tumors that have failed to respond to treatment with established clinically useful drugs, either from the start of treatment or during continuing treatment after initial useful response.

Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents.

Other investigators have demonstrated that dihydroxyanthracenedione (DiOHA) and anthracenedione acetate (AA) are active against a broad spectrum of transplantable mouse tumors. DiOHA and AA are in clinical trial in the US; AA is in clinical trial in Europe. Because of the broad spectrum of activity of these DNA binders against murine tumors and due to their promising clinical utility, we have evaluated these agents in combination with a variety of clinically useful antitumor drugs.

Toxicity and anticancer activity of a new triazine antifolate (NSC 127755).

A new triazine folate antagonist, 3-chloro-4-((4-(2-chloro-4-[4,6-diamino-2,2-dimethyl-s-triazin-1(2H)-yl]phenyl)butyl)) benzenesulfonyl fluoride compounded with ethanesulfonic acid (1:1) (NSC 127755), was highly active against four transplantable colon adenocarcinomas (36, 38, 10/A, 12/A) and the Dunning murine ovarian tumor M5076. Treatment schedule studies indicated that a prolonged time of exposure provided optimum antitumor activity for the compound. The combination of NSC 127755 plus 4-amino-1-[5-O-(1-oxohexadecyl)-beta-D-arabinofuranosyl]-2(1H)-pyrimidinone (palmO-ara-C, NSC 135962) was found to have therapeutic synergism against grossly evident colon adenocarcinoma 36.

Synergistic antileukemic activity of combinations of two nitrosoureas.

A rationale based on known chemical, biochemical, and biologic properties of nitrosoureas led to the testing of combinations of CCNU with chlorozotocin for in vivo activity against L1210 leukemia. Several combinations yielded synergistic antileukemic activity.

[Pharmacokinetic of antibiotics in patients with mucoviscidosis (author's transl)].

Inadequate therapeutic results in the treatment of bacterial infections in patients with Cystic Fibrosis prompted a reevaluation of pharmacokinetic parameters of orally and parenterally administered drugs in these patients. Gentamicin, Azlocillin and Ticarcillin are eliminated faster in patients with Cystic Fibrosis. Serum concentrations show a rapid decrease over 60 to 90 minutes and surpass MIC values of Pseudomonas isolates for a maximum of only 60 minutes.

Characterization of the biochemical basis of a complete deficiency of the adenine phosphoribosyl transferase (APRT).

In order to study the biochemical basis of a complete deficiency of adenine phosphoribosyl transferase (APRT) the enzyme was purified to homogeneity, its properties were characterized, and antibodies raised. The enzyme is indirectly involved in adenine uptake. Apparently, by forming AMP the internal concentration of adenine is kept low allowing it diffusion.

Clinical concepts derived from animal chemotherapy studies.

Animal chemotherapy studies have contributed significantly to clinical concepts in tumor therapy. Preclinical investigations have led to the discovery of new drugs and have demonstrated that it is possible to cure advanced metastatic neoplasia. A fundamental clinical concept stemming from animal chemotherapy studies is that increased selectivity and improved therapeutic effectiveness of antitumor agents may result from appropriate pharmacologic, biochemical, and biologic manipulation of the host-tumor drug relationship.

Absence of delayed lethality in mice treated with aclacinomycin A.

Two compounds that bind to or intercalate with DNA (DNA binders), e.g., adriamycin and 'dihydroxyanthracenedione', 9,10-anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)-amino]ethyl]amino]-, dihydrochloride salt, consistently caused delayed lethality (20-200 days after treatment) if administered intraperitoneally (IP).

[Aarskog syndrome (author's transl)].

Report of radiologic and hormonal results of a patient with typical stigmata of the Aarskog-syndrome. X-Ray findings are not been found to give diagnostic clues, whereas the hormonal findings are considered specific-typical: FSH and LH levels prior to orchidopexy are in a range are as seen with hypergonadotropic hypogonadism. One year after the orchidopexy LH values were found to be normal, the FSH again showed increased titer.

Erythro-9-(2-hydroxy-3-nonyl) Adenine alone and in combination with 9-beta-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in mice.

Although the antiviral activity of erythro-9-(2-hydroxy-3-nonyl)adenine, a potent adenosine deaminase inhibitor, against herpes simplex virus type 1 in cell culture was readily confirmed, the compound was found to be totally ineffective in the treatment of experimentally induced systemic herpes simplex virus type 1 infections in Swiss mice. Data were obtained, however, which clearly indicated that the antiviral potency of 9-beta-D-arabinofuranosyladenine in vivo could be enhanced by the co-administration of low, nontoxic doses of erythro-9-(2-hydroxy-3-nonyl)adenine.

Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.

The 2-fluoro derivative of 9-beta-D-arabinofuranosyladenine (2-F-ara-A) and its soluble 5'-formate and 5'-phosphate derivatives were therapeutically effective against the parent leukemia L1210 (L1210/0). 2-F-ara-A and 9-beta-D-arabinofuranosyladenine 5'-formate were inactive aginst a 1-beta-D-arabinofuranosylcytosine-resistant subline (L1210/ara-C) that was deficient in deoxycytidine kinase. Deoxycytidine prevented 2-F-ara-A-induced inhibition of proliferation of L1210/0 cells in culture and alleviated 2-F-ara-a inhibition of DNA synthesis.

Raised somatomedin associated with normal growth hormone. A cause of Beckwith-Wiedemann syndrome?

A child with Beckwith-Wiedemann syndrome is described. Growth hormone levels were normal, but circulating somatomedin activity was increased. The role of somatomedins in this condition, and the possibility of a feedback mechanism controlling somatomedin production are discussed.